Version history

{
  "description": "Falsifiable prediction from high-scoring hypothesis (score=0.728, gene=GPR43 (FFAR2)). Hypothesis: Does restoring gut-microbiome-derived SCFA (butyrate/propionate) levels rescue microglial GPR43-mediated HDAC inhibition and reduce NF-κB-driven neuroinflammation in early AD? Success criteria: 1. FMT from SCFA-supplemented donors reduces IBA1+/CD68+ microglia in 5xFAD mice by >30% vs FMT from vehicle controls. 2. GPR43-KO microglia show >50% increase in TNF-α/IL-6 vs WT under butyrate-reduced conditions. 3. HDAC3 inhibitor (RGFP966) reduces NF-κB p65 acetylation and IL-1β secretion by >40% in butyrate-depleted primary microglia. 4. CSF IL-1β decreases by >25% in SCFA-supplemented 5xFAD mice after 8 weeks.",
  "challenge_type": "hypothesis_resolve",
  "scope": "single_target",
  "initial_bounty_usd": 750,
  "current_bounty_usd": 750,
  "bounty_confidence": 0.7,
  "market_price": 0.5,
  "composite_score": 0.728246,
  "debate_count": 0,
  "status": "open",
  "question": "Does restoring gut-microbiome-derived SCFA (butyrate/propionate) levels rescue microglial GPR43-mediated HDAC inhibition and reduce NF-κB-driven neuroinflammation in early AD?",
  "domain": "neurodegeneration",
  "triggered_by": "hypothesis-auto-create"
}